Stay updated with breaking news from Planegg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
EQSAdhoc MorphoSys AG Key word Study results Ad hoc MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Po
EQS-News: MorphoSys AG / Key word(s): Quarterly / Interim StatementMorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results 15.11.2023 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, November 15, 2023 MorphoSys AG...
The drug researcher Morphosys is approaching the publication of the study results for the important hopeful drug Pelabresib. The highly anticipated data on the cancer drug are now expected by the end...
EQS Voting Rights Announcement: MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of...
![MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution -November 14, 2023 at 10:01 am EST - Vimarsana News](https://www.marketscreener.com/images/twitter_MS_fdnoir.png)
EQS Voting Rights Announcement: MorphoSys AG MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of...